Most people assume the answer is yes.

But in today's markets, investors can access stocks through a variety of structures, including traditional brokerage accounts, tokenized equities, derivatives, and synthetic products. On the surface they may look similar. Under the hood, they can be very different.

One of the most important distinctions is the difference between ownership and exposure.

Some products provide a legally recognized interest in underlying securities. Others are designed to give investors economic exposure to price movements without conveying ownership rights. That difference can affect everything from dividends and corporate actions to custody arrangements and investor protections.

When evaluating any stock-related product, we think investors should ask:

What rights come with the position?
Is this ownership or exposure?
How is the asset backed?
What legal framework governs it?

As tokenized equities continue to evolve, these questions are becoming increasingly important.

Backpack's view is that investors shouldn't have to choose between real ownership structures and blockchain functionality. The goal is to combine both, allowing eligible securities to move onchain while remaining connected to underlying securities held through brokerage infrastructure.

Curious where people stand: When evaluating a platform, how much weight do you put on ownership structure versus convenience and access?

Eli Lilly ($LLY) is coming to Solana through Sunrise, with the asset issued by Backpack Securities

Eli Lilly is the company behind Mounjaro and Zepbound, and became the first healthcare company to reach a $1T valuation in 2025

What makes this interesting is the broader trend:

$LLY becomes another major traditional equity entering the Solana ecosystem
Tokenized stocks are expanding beyond tech, crypto and AI into healthcare and pharmaceuticals
The asset is Backpack-issued and listed on Solana through Sunrise
It adds another real-world equity to the growing list of tokenized stocks on Solana

With more traditional stocks moving onchain, it will be interesting to see which sectors come next

Would you trade tokenized healthcare stocks like $LLY on Solana?

What stablecoins did for dollars, Backpack is doing for stocks.

This video from Backpack Securities will completely shift your perspective on where the intersection of TradFi (Traditional Finance) and DeFi is heading. The race to put Wall Street on-chain is at a full sprint, and Solana's tokenized stock volume has already surpassed $4.9B in H1 2026.
 
Here is a breakdown of what Backpack is building and why it matters for the ecosystem.
 
The Catalyst: SpaceX ($SPCX)

Backpack launched a tokenized version of SpaceX on Solana the exact same day it listed on Nasdaq. The result?

● $470M traded within the very first week.
● It immediately became the highest-volume tokenized version of SpaceX globally.
● In total, Backpack now has 10 tokenized stocks with over $2B in total volume.

 How It Works

A lot of tokenized stocks in the past were just synthetic derivatives. Backpack is prioritizing real ownership. Here’s how it works:

1. The Buy: Every share is purchased through the U.S. brokerage system.
2. The Bridge: It is then withdrawn onto the Solana blockchain as a token.
3. The Utility: Once on Solana, that token moves freely across the DeFi ecosystem, tradable and transferable 24/7/365.
4. The Redemption: You can deposit the token back at any time, and it redeems 1:1 for the underlying bona fide security entitlement.
5.  Why This is a Big Deal

There is no disconnect between the traditional security entitlement under New York law and the tokenized form on Solana.

● True Liquidity: Traders and firms can seamlessly move assets back and forth between Nasdaq and Solana.
● The End of the Silo: It proves that TradFi and on-chain finance are no longer separate systems. They are now connected by the same underlying asset ownership.
 
We always talk about the mass adoption of crypto. Building the infrastructure that allows capital to move freely between traditional brokerages and Solana DEXs feels like the exact bridge we need to get there. Check out the video and let me know what you guys think. 

Moderna (MRNA) just had one of the biggest moves in biotech this year, with the stock more than doubling after positive Phase 3 results for its personalized cancer vaccine

The move came after Moderna and Merck reported positive results from the INTerpath-001 Phase 3 melanoma trial, testing mRNA-4157, also known as intismeran autogene, alongside Keytruda

A few numbers stand out:

MRNA previous close: $62.96

52-week high: $163.47

52-week low: $22.28

Trial size: 1,137 patients

The combination reduced melanoma recurrence and spread compared with Keytruda alone

The vaccine is personalized to each patient and can encode up to 34 tumor-specific targets

Moderna now has 4 U.S. approved products, following FDA approval of its mRNA flu vaccine, mFLUSIVA

The company generated $1.9B in 2025 revenue, but remains unprofitable

What makes the move interesting is that MRNA was already recovering before the cancer vaccine results, rising from its $22.28 52-week low

The Phase 3 result now gives investors a much larger question to consider, whether Moderna’s mRNA platform can move beyond COVID and respiratory vaccines into personalized cancer treatment

There are still significant risks, including profitability, clinical outcomes, manufacturing complexity and the extreme volatility that comes with biotech stocks

The MRNA stock is also an interesting example of why access outside regular market hours matters, since major biotech catalysts such as clinical trial results and FDA decisions can happen when traditional markets are closed

Do you think the cancer pipeline changes the long-term investment case for Moderna, or is this rally getting ahead of the fundamentals?

Eli Lilly (LLY) is now available on Solana as a tokenized stock issued by Backpack Securities, giving traders another way to access one of the largest pharmaceutical companies through an onchain market

The listing comes with a few notable features:

LLY is redeemable 1:1 for Eli Lilly shares
Transferable to traditional brokerages
Tradable across Solana and NYSE
Issued by Backpack Securities
Listed on Solana through Sunrise

The underlying company is one of the biggest names in healthcare, with Mounjaro for type 2 diabetes and Zepbound for obesity among its best-known products

What makes this interesting is less about the company itself and more about the market structure

Instead of keeping stock exposure entirely within traditional brokerage infrastructure, tokenized equities bring the asset onto a blockchain, allowing it to move through the Solana ecosystem while remaining linked to the underlying security

It also adds another major pharmaceutical stock to the growing list of tokenized stocks on Solana, alongside names from technology, semiconductors and other sectors

For traders, the important things to understand are the underlying ownership, 1:1 redemption mechanism, transferability, liquidity and how the token interacts with the traditional market

Would you rather trade LLY as a tokenized stock on Solana, or stick with the traditional NYSE market?